Our findings suggest that parthanatos activation may serve as a potential biomarker of resistance to PARP inhibitors in breast cancer, which could help refine patient selection and enable more precise identification of individuals likely to benefit from PARP inhibitor therapy. This evidence concerns the gene PARP1 and breast carcinoma.